Therapy pacemaker receives FDA Approval

24th August 2017
Posted By : Enaie Azambuja
Therapy pacemaker receives FDA Approval

BIOTRONIK has announced FDA approval and commercial availability of Edora HF-T QP, an MR conditional quadripolar (QP) cardiac resynchronisation therapy pacemaker (CRT-P) with MRI AutoDetect technology. With a volume of 15 cc, Edora HF-T QP is the smallest MR conditional CRT-P available in the US with longevity of nearly 10 years, reducing the frequency of device replacements for heart failure patients.

Edora HF-T QP features MRI AutoDetect, Closed Loop Stimulation (CLS) and BIOTRONIK Home Monitoring with automatic, daily transmission verification. BIOTRONIK Home Monitoring is the only cardiac device remote monitoring system clinically proven to improve health outcomes in heart failure.

In recent studies, BIOTRONIK Home Monitoring was associated with a greater than 50% reduction in mortality due to heart failure2 and a 36% reduction in hospitalisation for worsening heart failure.

“Patient care is a constant journey. It doesn’t end when the patient leaves my office or recovers from a procedure. As healthcare providers, we must think beyond today and help ensure patients are appropriately cared for throughout their lifetime,” said Dr. Roderick Tung, a cardiac electrophysiologist in Chicago.

“MR conditional CRT-Ps that can be programmed to automatically switch to MRI mode when they enter the MRI environment are another significant step in delivering the best possible care throughout the patient journey. This technology eliminates an office visit for patients and decreases administrative burden for providers. The impact is significant, especially in institutions that perform cardiac MRI for advanced ventricular care."

BIOTRONIK’s MRI AutoDetect technology is designed to improve patient safety by minimising the time the device is in MRI mode and remedying logistical programming challenges for physicians and health systems. Once activated by a clinician, MRI AutoDetect automatically recognises when a patient enters an MRI field and changes the device programming to MRI mode.

“With the launch of Edora HF-T QP, BIOTRONIK offers a full suite of ProMRI products ensuring physicians can always choose MRI conditional devices for their patients,” said Marlou Janssen, President of BIOTRONIK, Inc.

“Our devices are the only FDA-approved CRM solutions that provide automatic detection of an MRI environment, physiologic rate adaptation and automatic daily remote monitoring. These are differentiators that contribute to personalised and preventive care that impacts long-term health outcomes.”

The BIOTRONIK Home Monitoring system includes the Heart Failure Monitor Online, a summary of nine long-term heart failure statistics including thoracic impedance. When combined with daily updates, this allows physicians to continuously monitor and evaluate patients’ heart failure status.

Equipped with comprehensive patient monitoring and easily accessible statistical trends, physicians can review individual patient data quicker, leading to early intervention and better outcomes.


You must be logged in to comment

Write a comment

No comments

Sign up to view our publications

Sign up

Sign up to view our downloads

Sign up

Medical Japan 2018
21st February 2018
Japan INTEX Osaka
Med-Tech Innovation Expo 2018
25th April 2018
United Kingdom Ricoh Arena, Coventry